By interacting with TIGIT, NECTIN2 was found to be highly expressed in metastatic non-TNBC cells, and by interacting with TIGIT, metastatic cancer cells were found to inhibit T-cell activation and suppress the immune response [19, 39, 48]. Here, NECTIN2 is linked to metastatic malignant neoplasm.